Novo Nordisk CEO on Catalent, Ozempic and Wegovy

Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic.

--------
Connect with us on...

[Four_Eyes]

I like how this dude just answers the questions.

[jacobriis]

In Danish it's semaglutid. The d is soft. So a bit difficult for Americans. But many people in Denmark use the English semaglutide

[vidadormer]

The biggest problem is the counterfeit and manufactured chemists and pharmacies manufacturing counterfeit products and you are not controlling it especially in the third-world countries in Africa…and branches of Novo Nordisk not taking responsibility for counterfeit products being supplied to innocent patients and citizens

[its_jawsh]

As a pharm tech and someone who’s going to pharmacy school this company makes amazing products but they simultaneously have encouraged the use of type 2 diabetic products by fat people. I have patients who cannot get their Trulicity, Ozempic, Wegovy, and Victoza because of their very powerful ad campaign and pushing. It’s a waste of medication in a very low supply environment. Type 2 diabetics NEED this medication and should be first in line, fat people second.

[chrimbus]

Taking drugs to get slim, what could go wrong. I mean nothing has gone wrong in the past, this time its different I suppose.🤣

[marketsqueezer]

It cost almost nothing to make NOVO products